EndoArt® Implantation in Subjects With Chronic Corneal Edema

Corneal Edema Clinical Trial

Official title:

An Open-label Multicenter Phase 2 Clinical Safety Investigation of the EndoArt® Implantation in Subjects With Chronic Corneal Edema

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05139771
• Other study ID #: CLI-E033
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 30, 2021
• Est. completion date: December 31, 2023

Study information

• Verified date: February 2023
• Source: Eye-yon Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The EndoArt® is intended to be used as an endothelial prosthesis in patients with chronic corneal edema.The EndoArt® (Artificial Endothelial layer) is a permanent implant, constructed of a clear, transparent, foldable, biologically compatible copolymer of hydroxyethyl methacrylate and methyl methacrylate. The peripheral surface of the EndoArt® has either one or more marks, to ensure the correct orientation of the implant. The device serves as a physical barrier blocking the influx of water from the AC of the eye into the cornea due to dysfunctional corneal endothelial layer. Together with evaporation from the anterior surface of the cornea it maintains corneal hydration and clarity. The EndoArt® device is CE marked approved (approved for marketing by the European regulatory authority).

Description:

This study is a prospective, multicenter, open-label, phase 2 clinical investigation assessing safety of EndoArt® implantation, in subjects with chronic corneal edema. Safety will be assessed by evaluating the rate of adverse events and adverse device effects throughout the study period. Exploratory efficacy endpoints will be assessed by measuring the change in corneal thickness from baseline, change in pain score from baseline and changes in visual acuity. Time to, and rate of, post-surgical rebubbling to facilitate adhesion of the device will be explored. Subjects with chronic corneal edema that meet the inclusion/exclusion criteria will be the study target population. The study will encompass a total of up to 80 subjects who will complete the Protocol follow-up schedule. For the Primary endpoint, the frequency and severity of device related adverse events, from patient entry through the 6-month follow-up period will be analyzed. Adverse events will be assessed on a continuous basis and will continue to be collected for 12 months. This clinical investigation is conducted in up to 12 (twelve) clinical sites in Europe (Germany, France, and Netherlands), Mexico, India and Israel. Additional sites may be considered. This clinical investigation has been designed to provide continuous clinical evidence for the EndoArt® as part of its clinical follow up program.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 52
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

Individuals must meet the following inclusion criteria at screening visit:

1. Male or Female subjects 40-85 years of age.

2. Have chronic corneal edema (for a minimum of 3 months) secondary to endothelial dysfunction.

3. Have corneal thickness >600µm by OCT.

4. Have best corrected distance visual acuity 6/19 (20/63) or worse (equivalent ETDRS= 60 letters) with subjective symptoms of impaired visual function.

5. Subject with posterior pseudophakia and stable IOL.

6. Willing and able to understand and sign informed consent prior to any study related procedure.

7. Willing and able to follow study instructions (e.g., to lay on one's back for 4 hours post op), able to self-administer or have caregiver available to administer eyedrops as required by the protocol for the duration of the study, and able to attend study visits/assessments for the duration of the study. Exclusion Criteria: Individuals for participation will be ineligible for the study if any of the following

conditions apply:

1. History of ocular Herpetic keratitis.

2. Scarred cornea resulting in visual impairment with intact endothelium (cell density = 1500).

3. History of posterior vitrectomy.

4. Post PKP

5. Have an irregular posterior cornea (e.g., post trauma).

6. Have a current infection of the cornea.

7. Have band keratopathy and/or limbal stem cell deficiency.

8. Have clinically severe dry eye disease which needs more than 4 drops of lubricant per day.

9. Phthisis bulbi or subject is at risk of developing phthisis.

10. Subject with medically uncontrolled high intra ocular pressure.

11. Aphakia.

12. Anterior chamber IOL or fixated anterior chamber IOL.

13. Pseudophakodonesis.

14. Have large iris defect which could compromise intraoperative air bubble formation

15. Have undergone corneal refractive surgery.

16. History of neurotrophic cornea.

17. History of recurrent corneal erosion or persistent epithelial defect.

18. IridoCorneal Endothelial (ICE) Syndrome or any rare disease/ syndrome creating anatomical or physiological anomalies of the anterior chamber (e.g., corectopia).

19. Recurrent posterior, intermediate or anterior uveitis.

20. Subject receiving regular intravitreal injection

21. Currently participating or have participated in an investigational study, other than this study, within the past 60 days.

Related Conditions & MeSH terms

• Corneal Edema
• Edema

Intervention

Device:
• THE ENDOART® IMPLANTATION (Artificial Endothelial layer)
Implantation of EndoArt® is similar to other anterior segment surgical procedures such as DSAEK/DMEK.

Locations

Country	Name	City	State
France	Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)	Brest
France	Hôpital Fondation A. de Rothschild	Paris
Georgia	Akhali Mzera Eye Clinic	Tbilisi
Georgia	Caucasus Medical Center (CMC)	Tbilisi
Georgia	Davinci Eye Medical Center	Tbilisi
Georgia	High Technology Medical Center, University Clinic	Tbilisi
Germany	International Vision Correction Research Centre (IVCRC) Universitätsklinikum Heidelberg	Heidelberg
India	L V Prasad Eye Institute	Hyderabad	Telangana
India	Dr Agarwal's Eye Hospital	Tirunelveli	Tamil Nadu
Israel	Rambam Medical Center	Haifa
Israel	Assuta HaShalom	Tel Aviv
Netherlands	Amsterdam MC (AMC)	Amsterdam

Sponsors (1)

Lead Sponsor	Collaborator
Eye-yon Medical

Countries where clinical trial is conducted

France,  Georgia,  Germany,  India,  Israel,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The frequency of device related adverse events (safety)	Adverse events will be assessed on a continuous basis from baseline until follow-ups completion.	12 months
Primary	The severity of device related adverse events (safety).	Adverse events will be assessed on a continuous basis from baseline until follow-ups completion.	12 months
Secondary	Change from baseline in central corneal thickness (CCT) postoperatively.	Central Corneal Thickness (pachymetry) will be measured by anterior segment Optical Coherence Tomography (OCT).	6 months
Secondary	Incidence of primary post-surgical detachment of the device.	Post implantation device detachment	12 months
Secondary	Rate of rebubbling post-op.	Number of times that post implantation re-bubbling is done	12 months
Secondary	Change in Best Corrected Distance Visual Acuity (BCDVA) from baseline.	Visual acuity will be measured with ETDRS format charts.	12 months
Secondary	Change in ocular pain score as assessed by a Visual Analogue Scale (VAS) from baseline.	VAS is a horizontal line, 0-100 mm. VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the subject marks.	12 months